查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
注射筆市場：按類型、治療方法、最終用戶劃分：2021-2031 年全球機會分析和行業預測
市場調查報告書
商品編碼
1298210

注射筆市場：按類型、治療方法、最終用戶劃分：2021-2031 年全球機會分析和行業預測

Injection Pen Market By Type, By Therapy, By End Users : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 428 Pages | 商品交期: 2-3個工作天內

價格

2021 年註射筆市場價值為 378.99 億美元，預計 2031 年將達到 805.1151 億美元，2022 年至 2031 年復合年增長率為 7.8%

注射筆是一種用於注射的醫療器械。 它由一個類似筆的裝置組成，帶有針頭、注射器和控製劑量的柱塞。 注射筆的設計是為了方便注射。 它通常用於施用胰島素和其他藥物。 市場上有一次性和可重複使用的類型。 一次性筆預先裝滿藥物，當藥筒空時就被丟棄。 另一方面，可重複使用的筆與藥筒一起使用，藥筒裝入筆中並在使用藥物後丟棄，使筆為下一個藥筒做好準備。

注射筆市場-IMG1

糖尿病、骨質疏鬆症、心血管疾病、多發性硬化症等慢性疾病的患病率上升以及老年人口的迅速增加是推動注射筆市場增長的主要因素。 此外，慢性病是全世界死亡的主要原因，由於生活方式的改變、人口老齡化和不健康的飲食，其患病率正在增加。 例如，根據美國疾病控制與預防中心 (CDC) 的數據，截至 2021 年，預計將有 1.17 億美國成年人 (47.4%) 患有至少一種慢性病。 最流行的慢性病是心髒病（4580萬人受影響）、關節炎（4340萬人受影響）、糖尿病（3420萬人受影響）、高血壓（3350萬人受影響）、癌症（13.7億人受影響）、哮喘、中風、腎臟疾病和阿爾茨海默病。 因此，慢性病患病率的激增預計將推動市場增長，並增加對技術先進的注射筆的關注。

然而，在北美等一些地區，注射筆的高成本和替代藥物輸送方法的可用性限制了市場的增長。 相反，由於糖尿病人口增加，慢性病患病率上升以及新興國家對胰島素注射筆的需求增加可能會為註射筆開闢新的市場潛力，該市場潛力將在預測期內繼續增長。預計將為市場提供利潤豐厚的機會生長。

北美將在 2021 年佔據注射筆市場的大部分份額，並預計在預測期內仍將佔據主導地位。 該市場主要由高可支配收入和強大的醫療基礎設施驅動。 此外，該地區擁有發達的製藥業和高度的醫療保健意識，有助於開發和引進創新技術，例如用於廣泛治療應用的注射筆。 此外，Sanofi、Eli Lilly、Novo Nordisk、Becton Dickinson等主要市場參與者的增加正在大力投資研發，以推出提供各種注射筆的創新產品，這正在推動注射筆市場的發展。預計將促進這一地區的增長。

預計亞太地區在預測期內將創下最快的複合年增長率。 這是由於老年人口迅速增長、糖尿病等慢性病患病率上升、收入迅速增長、對醫療產品的需求不斷增加以及醫療基礎設施的改善。 此外，亞太地區是主要製藥和醫療器械製造商的所在地，從而增加了高品質注射筆的產量，推動了市場的增長。

內容

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資領域
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 協調員
      • 慢性疾病增加
      • 增強自我注入意識
      • 不斷進步的技術
    • 制約因素
      • 偏好替代藥物輸送模式
      • 針刺傷增加
    • 機會
      • 新興經濟體的高增長潛力。
  • COVID-19 對市場的影響分析

第 4 章註射筆市場：按類型

  • 概述
    • 市場規模和預測
  • 一次性注射筆
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 可重複使用的注射筆
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第五章註射筆市場：按處理方式

  • 概述
    • 市場規模和預測
  • 糖尿病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 生長激素
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 骨質疏鬆症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 不孕症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 6 章註射筆市場：按最終用戶劃分

  • 概述
    • 市場規模和預測
  • 家庭護理領域
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 醫院和診所
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第七章註射筆市場：按地區

  • 概述
    • 市場規模和預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模和預測：按處理方法分類
    • 市場規模和預測：按最終用戶劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模和預測：按處理方法分類
    • 市場規模和預測：按最終用戶劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模和預測：按處理方法分類
    • 市場規模和預測：按最終用戶劃分
    • 市場規模/預測：按國家/地區劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模和預測：按處理方法分類
    • 市場規模和預測：按最終用戶劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按類型
      • 市場規模和預測：按處理方法分類
      • 市場規模和預測：按最終用戶劃分

第 8 章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 頂級公司定位（2021 年）

第 9 章公司簡介

  • Eli Lilly and Company
  • AstraZeneca
  • Ypsomed AG
  • Becton, Dickinson and Company
  • Merck Group
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Novo Nordisk A/S
  • Biocon
Product Code: A07629

The injection pen market valued for $37,899.00 million in 2021 and is estimated to reach $80,511.51 million by 2031, exhibiting a CAGR of 7.8% from 2022 to 2031. An injection pen is a medical device used to administer injections. It consists of a needle, a syringe and a pen-like device with a plunger that controls the amount of medication administered. The injection pen is designed to administer injections conveniently. It is commonly used to administer insulin and other medications. It is available in disposable and reusable type in the market. Disposable pens are preloaded with drug and are thrown away after the drug cartridge is empty. Whereas, reusable pens work with drug cartridges that can be loaded into the pen and then thrown away once the drug is used, leaving the pen ready for the next cartridge.

Injection Pen Market - IMG1

The key factor that drives the growth of the injection pen market is the rise in the prevalence of chronic disease such as diabetes, osteoporosis, cardiovascular diseases, and multiple sclerosis, and surge in geriatric population. In addition, chronic diseases are the leading cause of death worldwide, and their prevalence is increasing due to lifestyle changes, aging population, and unhealthy diets. For instance, according to the Centers for Disease Control and Prevention (CDC), an estimated 117 million U.S. adults (47.4%) have at least one chronic health condition as of 2021. The most prevalent chronic diseases are, heart disease (affecting 45.8 million people), arthritis (affecting 43.4 million people), diabetes (affecting 34.2 million people), high blood pressure (affecting 33.5 million people), cancer (affecting 13.7 million people), and various others such as asthma, stroke kidney disease and Alzheimer's disease. Thus, surge in prevalence of chronic diseases, has increased the focus on the technologically advanced injection pen that is anticipated to boost the growth of the market.

However, high cost of injection pen in some regions such as North America and availability of alternative methods for drug delivery restrain the growth of the market. Conversely, rise in prevalence of chronic diseases and increase in demand for injection pen for insulin from emerging economies owing to rise in diabetic cases may open up new market potential for injection pen and is expected to provide a lucrative opportunity for the growth of the market during the forecast period.

North America accounted for a majority of the injection pen market share in 2021 and is anticipated to remain dominant during the forecast period. The injection pen market is mainly driven by high disposable income, and strong medical infrastructure. In addition, the region has a well-established pharmaceutical industry and a high level of healthcare awareness, which has enabled it to develop and implement innovative technologies, such as injection pens, for a wide range of therapeutic applications. Furthermore, the increase in number of key market players such as Sanofi, Eli Lilly, Novo Nordisk, and Becton Dickinson, which have invested heavily in research and development to come up with innovative products to provide a wide range of injection pen is expected to fuel the market growth in this region.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is due to the presence of a rapidly growing geriatric population, rise in incidences of chronic diseases such as diabetes, surge in income, increase in demand for medical products, and improvement in the healthcare infrastructure. In addition, Asia-Pacific is a home to major drug and medical device manufacturers, leading to increased production of high-quality injection pens that drives the growth of the market.

The injection pen market is segmented on the basis of type, therapy, end user, and region. By type, the market is divided into disposable injection pen and reusable injection pen. By therapy the market is bifurcated into diabetes, growth hormone, osteoporosis, fertility, and others. By end user, it is categorized into home-care settings and hospital & clinics. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in the injection pen market are: Eli Lily and Company, Novo Nordisk A/S, Sanofi, Biocon, AstraZeneca, Pfizer Inc, Becton, Dickinson and Company, Ypsomed AG, Novartis AG and Merck KGaA.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the injection pen market analysis from 2021 to 2031 to identify the prevailing injection pen market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the injection pen market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global injection pen market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

  • Growth Hormone
  • Osteoporosis
  • Fertility
  • Others
  • Diabetes

By End Users

  • Home-care Settings
  • Hospital and clinics

By Type

  • Disposable injection pen
  • Reusable injection pen

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • AstraZeneca
  • Ypsomed AG
  • Becton, Dickinson and Company
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Eli Lilly and Company
  • Merck Group
  • Novo Nordisk A/S
  • Biocon

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of chronic disease.
      • 3.4.1.2. Surge in awareness for self-injectables
      • 3.4.1.3. Rise in technological advancement
    • 3.4.2. Restraints
      • 3.4.2.1. Preference for alternative drug delivery modes
      • 3.4.2.2. Increase in the number of needlestick injury
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies.
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: INJECTION PEN MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Disposable injection pen
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Reusable injection pen
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: INJECTION PEN MARKET, BY THERAPY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Diabetes
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Growth Hormone
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Osteoporosis
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Fertility
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Others
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country

CHAPTER 6: INJECTION PEN MARKET, BY END USERS

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Home-care Settings
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Hospital and clinics
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: INJECTION PEN MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Therapy
    • 7.2.4. Market size and forecast, by End Users
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Therapy
      • 7.2.5.1.4. Market size and forecast, by End Users
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Therapy
      • 7.2.5.2.4. Market size and forecast, by End Users
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Therapy
      • 7.2.5.3.4. Market size and forecast, by End Users
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Therapy
    • 7.3.4. Market size and forecast, by End Users
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Therapy
      • 7.3.5.1.4. Market size and forecast, by End Users
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Therapy
      • 7.3.5.2.4. Market size and forecast, by End Users
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Therapy
      • 7.3.5.3.4. Market size and forecast, by End Users
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Therapy
      • 7.3.5.4.4. Market size and forecast, by End Users
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Therapy
      • 7.3.5.5.4. Market size and forecast, by End Users
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Therapy
      • 7.3.5.6.4. Market size and forecast, by End Users
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Therapy
    • 7.4.4. Market size and forecast, by End Users
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Therapy
      • 7.4.5.1.4. Market size and forecast, by End Users
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Therapy
      • 7.4.5.2.4. Market size and forecast, by End Users
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Therapy
      • 7.4.5.3.4. Market size and forecast, by End Users
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Therapy
      • 7.4.5.4.4. Market size and forecast, by End Users
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Therapy
      • 7.4.5.5.4. Market size and forecast, by End Users
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Therapy
      • 7.4.5.6.4. Market size and forecast, by End Users
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Therapy
    • 7.5.4. Market size and forecast, by End Users
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Therapy
      • 7.5.5.1.4. Market size and forecast, by End Users
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Therapy
      • 7.5.5.2.4. Market size and forecast, by End Users
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Therapy
      • 7.5.5.3.4. Market size and forecast, by End Users
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Therapy
      • 7.5.5.4.4. Market size and forecast, by End Users

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Eli Lilly and Company
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. AstraZeneca
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Ypsomed AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Becton, Dickinson and Company
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Merck Group
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Sanofi
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Novo Nordisk A/S
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Biocon
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 02. INJECTION PEN MARKET FOR DISPOSABLE INJECTION PEN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. INJECTION PEN MARKET FOR REUSABLE INJECTION PEN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 05. INJECTION PEN MARKET FOR DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. INJECTION PEN MARKET FOR GROWTH HORMONE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. INJECTION PEN MARKET FOR OSTEOPOROSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. INJECTION PEN MARKET FOR FERTILITY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. INJECTION PEN MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 11. INJECTION PEN MARKET FOR HOME-CARE SETTINGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. INJECTION PEN MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. INJECTION PEN MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. U.S. INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 19. U.S. INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 20. U.S. INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 21. CANADA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 22. CANADA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 23. CANADA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 37. UK INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. UK INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 39. UK INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 40. ITALY INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. ITALY INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 42. ITALY INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 56. CHINA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. CHINA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 58. CHINA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 59. AUSTRALIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. AUSTRALIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 62. INDIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. INDIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 64. INDIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH AFRICA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 87. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 88. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 89. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 90. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 91. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 92. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 93. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 94. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 95. ASTRAZENECA: KEY STRATERGIES
  • TABLE 96. YPSOMED AG: KEY EXECUTIVES
  • TABLE 97. YPSOMED AG: COMPANY SNAPSHOT
  • TABLE 98. YPSOMED AG: PRODUCT SEGMENTS
  • TABLE 99. YPSOMED AG: PRODUCT PORTFOLIO
  • TABLE 100. YPSOMED AG: KEY STRATERGIES
  • TABLE 101. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 102. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 103. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
  • TABLE 104. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 105. MERCK GROUP: KEY EXECUTIVES
  • TABLE 106. MERCK GROUP: COMPANY SNAPSHOT
  • TABLE 107. MERCK GROUP: PRODUCT SEGMENTS
  • TABLE 108. MERCK GROUP: PRODUCT PORTFOLIO
  • TABLE 109. PFIZER INC.: KEY EXECUTIVES
  • TABLE 110. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 111. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 112. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 113. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 117. SANOFI: KEY EXECUTIVES
  • TABLE 118. SANOFI: COMPANY SNAPSHOT
  • TABLE 119. SANOFI: PRODUCT SEGMENTS
  • TABLE 120. SANOFI: PRODUCT PORTFOLIO
  • TABLE 121. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 122. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 123. NOVO NORDISK A/S: PRODUCT SEGMENTS
  • TABLE 124. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 125. BIOCON: KEY EXECUTIVES
  • TABLE 126. BIOCON: COMPANY SNAPSHOT
  • TABLE 127. BIOCON: PRODUCT SEGMENTS
  • TABLE 128. BIOCON: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. INJECTION PEN MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF INJECTION PEN MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN INJECTION PEN MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALINJECTION PEN MARKET
  • FIGURE 10. INJECTION PEN MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR DISPOSABLE INJECTION PEN, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR REUSABLE INJECTION PEN, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. INJECTION PEN MARKET, BY THERAPY, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR DIABETES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR GROWTH HORMONE, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR OSTEOPOROSIS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR FERTILITY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. INJECTION PEN MARKET, BY END USERS, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR HOME-CARE SETTINGS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. INJECTION PEN MARKET BY REGION, 2021
  • FIGURE 23. U.S. INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA INJECTION PEN MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: INJECTION PEN MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. YPSOMED AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. YPSOMED AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. YPSOMED AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 56. BECTON, DICKINSON AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. MERCK GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. MERCK GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. MERCK GROUP: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 72. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. BIOCON: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. BIOCON: REVENUE SHARE BY SEGMENT, 2021 (%)